$0.364900
0.00431.19%
Pre-Market: 8:47 AM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Mustang Bio (NASDAQ:MBIO) Stock, Analyst Ratings, Price Targets, Forecasts
Mustang Bio Inc has a consensus price target of $10.5 based on the ratings of 4 analysts. The high is $18 issued by Cantor Fitzgerald on August 24, 2023. The low is $2 issued by HC Wainwright & Co. on May 16, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Cantor Fitzgerald on May 16, 2024, May 13, 2024, and August 24, 2023, respectively. With an average price target of $7.33 between HC Wainwright & Co., HC Wainwright & Co., and Cantor Fitzgerald, there's an implied 1909.68% upside for Mustang Bio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
BTIG
B. Riley Securities
1calculated from analyst ratings
Analyst Ratings for Mustang Bio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2024 | Buy Now | 448.1% | HC Wainwright & Co. | Joseph Pantginis | → $2 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 448.1% | HC Wainwright & Co. | Joseph Pantginis | $25 → $2 | Maintains | Buy | Get Alert |
| 08/24/2023 | Buy Now | 4832.86% | Cantor Fitzgerald | Kristen Kluska | → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 08/16/2023 | Buy Now | 6751.19% | HC Wainwright & Co. | Joseph Pantginis | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 4284.76% | BTIG | Justin Zelin | $20 → $16 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 6751.19% | HC Wainwright & Co. | Joseph Pantginis | → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | Buy Now | 5380.95% | BTIG | Justin Zelin | $4 → $20 | Maintains | Buy | Get Alert |
| 06/16/2023 | Buy Now | 6751.19% | HC Wainwright & Co. | Joseph Pantginis | → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 1818.33% | HC Wainwright & Co. | Joseph Pantginis | → $7 | Reiterates | Buy → Buy | Get Alert |
| 03/30/2023 | Buy Now | 1818.33% | HC Wainwright & Co. | Joseph Pantginis | → $105 | Reiterates | → Buy | Get Alert |
| 11/16/2022 | Buy Now | 996.19% | BTIG | Justin Zelin | $120 → $60 | Maintains | Buy | Get Alert |
| 01/24/2022 | Buy Now | 1544.29% | B. Riley Securities | Mayank Mamtani | $195 → $90 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Mustang Bio (MBIO) stock?
The latest price target for Mustang Bio (NASDAQ:MBIO) was reported by HC Wainwright & Co. on May 16, 2024. The analyst firm set a price target for $2.00 expecting MBIO to rise to within 12 months (a possible 448.10% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mustang Bio (MBIO)?
The latest analyst rating for Mustang Bio (NASDAQ:MBIO) was provided by HC Wainwright & Co., and Mustang Bio reiterated their buy rating.
When was the last upgrade for Mustang Bio (MBIO)?
There is no last upgrade for Mustang Bio
When was the last downgrade for Mustang Bio (MBIO)?
There is no last downgrade for Mustang Bio.
When is the next analyst rating going to be posted or updated for Mustang Bio (MBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mustang Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mustang Bio was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
Is the Analyst Rating Mustang Bio (MBIO) correct?
While ratings are subjective and will change, the latest Mustang Bio (MBIO) rating was a reiterated with a price target of $2.00 to $2.00. The current price Mustang Bio (MBIO) is trading at is $0.36, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.